Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $704.25K fell 88.5% year over year, behind the -18.6% change in trailing-twelve-month financing cash flow. Sequentially, it fell 71.3% from the prior quarter. Over 3 fiscal years it compounded at +35.8% a year.
Context
- Financing cash flow amounted to 1008.4% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -88.5% toward the trailing-twelve-month pace of -18.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 13.74M USD
- Year-over-year change
- +140.6%
- 4-year CAGR
- +13.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.74M | +140.6% |
| FY2024 | 2024-12-31 | 5.71M | +16.2% |
| FY2023 | 2023-12-31 | 4.92M | -10.4% |
| FY2022 | 2022-12-31 | 5.49M | -33.2% |
| FY2021 | 2021-12-31 | 8.22M | — |
Financing Cash Flow vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 financing cash flow of $8.35M is the smallest of the 9 companies compared; the peer median is $37.42M.
- Its year-over-year change of -18.6% is the lowest of 9, against a peer median of +109.0%.
- Financing cash flow amounts to 590.3% of revenue for COEP, versus a peer median of 459.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $126.68M | +124.3% | -81.5% | — | |
| LTM Mar 2026 | $79.85M | +91.7% | -46.3% | 52.8% | |
| LTM Mar 2026 | $65.68M | +25657.6% | — | — | |
| LTM Mar 2026 | $47.24M | +93.8% | -8.9% | 14179.4% | |
| LTM Mar 2026 | $27.6M | +300.6% | -21.2% | 84.3% | |
| LTM Mar 2026 | $19.12M | +27.6% | -10.3% | 833.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $13.6M | +3.6% | +1272.4% | — |
| LTM Mar 2026 | $9.76M | +768.9% | +174.4% | — | |
| LTM Mar 2026 | $8.35M | -18.6% | +35.8% | 590.3% | |
| Peer median (excluding COEP) | $37.42M | +109.0% | -10.3% | 459.0% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (11.92M) |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| Deferred Income Tax | 5.34M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 0 | 477.5K | 1.1M | 1.22M |
| Change in Working Capital | (2.98M) | (550.34K) | 1.73M | (125.26K) | (1.46M) |
| Accounts Receivables | 21.79K | (8.08K) | (30.9K) | (234.74K) | (7.35K) |
| Inventory | (422.02K) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | (35.07K) | 1.32M | (149.94K) | (381.01K) |
| Other Working Capital | (1M) | (507.19K) | 437.31K | 259.42K | (1.07M) |
| Other Non-Cash Items | 4.26M | 33.25M | 10.79M | 2.21M | 2.34M |
| Operating Cash Flow | (4.49M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
| Capital Expenditures | (1.75M) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.75M) | 0 | 0 | 0 | 0 |
| Debt Repayment | (1.62M) | (2.42M) | (575K) | 1.2M | 771.25K |
| Common Stock Issued | 10.14M | 3.27M | 5.29M | 100K | 12.97M |
| Common Stock Repurchased | (247.17K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.9K) | 4.63M | 200K | 500K | 0 |
| Financing Cash Flow | 8.22M | 5.49M | 4.92M | 5.71M | 13.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.98M | 1.61M | (2.32M) | (936.25K) | 5.14M |
| Free Cash Flow | (6.24M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.